(Q43254687)

English

Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience

scientific article published in October 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

(3aS)-palonosetron

1 reference

based on heuristic

inferred from title

author name string

P Rzepecki

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

W Pielichowski

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

S Oborska

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

J Barzal

4

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

B Mlot

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

language of work or name

0 references

publication date

1 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

3247-3249

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

Palonosetron (Aloxi): a second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

Economic Evaluation of a New Antiemetic Drug - Palonosetron versus Ondansetron : Assessment of the Drug Price Ratio in Five European Countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

Antiemetic control: toward a new standard of care for emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.07.071

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2009.07.071

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43254687&oldid=2124544797"